WIN 2014: TWO DAYS DEDICATED TO NEW APPROACHES TO PERSONALIZED MEDICINE
Winning combinations for precision cancer medicine – Breakthrough biomarker investigations and combined therapeutic approaches
Paris, June 27, 2014 - On the topic of Precision Medicine against Cancer, the 6th WIN symposium was attended by over 400 people from over 35 countries to discuss the progress in this area and in particular on combined biomarkers and targeted therapeutic approaches. WIN 2014 brought together a panel of internationally renowned experts representing all sectors of personalized medicine in cancer research: academics, clinicians, pharmaceutical and biotechnology industries, life sciences, health informatics, regulatory bodies and patient groups.
For the 6th consecutive year, the American Society of Clinical Oncology (ASCO *), ESMO, EORTC, ESO and UICC have accredited the WIN symposium. All emphasized the high quality of the scientific program. ”It can be difficult to treat a tumor if we are only targeting one pathway as often genetic mutations are found in several pathways. The objective of the combined therapeutic approach is to identify and test the combination of therapies such as inhibitors to target several pathways altered in the tumor” said John Mendelsohn, Chairman of WIN Consortium. During the two days, various experts exchanged views on this approach. ”Some associations of molecules are already being tested. Results of these studies are eagerly awaited and will contribute to the development of personalized cancer medicine “said Professor Alexander Eggermont, General Director of Gustave Roussy, Vice-Chairman of the WIN Consortium and Chairman of the 2014 WIN Symposium.
Four physicians-scientists of Gustave Roussy participated in this high-level international symposium. Professor Alexander Eggermont introduced and concluded the debates (searchable Programme). Dr. Vladimir Lazar, Department of Biology and Molecular Pathology Gustave Roussy and Chief Operating Officer of the WIN Consortium, moderated the plenary session on the blood and body fluids as a means of non-invasive study in oncology (eg. circulating tumor cells, circulating DNA …). Professor Jean-Charles Soria, Head, Department of therapeutic innovation and early phase clinical trials (DITEP) Gustave Roussy, was moderator of the session on combinations of targeted therapies. Professor Eric Solary, Research Director Gustave Roussy, focused upon mechanisms of resistance developed in some leukemias (myeloproliferative neoplasms) and the value of combining interferon with another therapy to circumvent them. Presentation Summary Eric Solary.
The aim of the WIN Consortium is to accelerate and coordinate the development of personalized medicine and support access for all by understanding all of its challenges (research, healthcare, technology, funding and health economics, benefit of the patient, public health…)”. Faced with these enormous challenges, Professor Alexander Eggermont said, “No team can work alone. WIN’s strategy is to identify innovative projects and organize global clinical validation studies of new biomarkers and new targeted therapies”. As co-founder of WIN, Gustave Roussy is a leading organization of the Consortium and participates actively in the development of personalized medicine.
About WIN Consortium:
WIN is an initiative from Gustave Roussy and University of Texas MDAnderson cancer center USA.
WIN is unique structurally in that it brings together organizations from academia, business and not-for-profit organizations to focus on translating the latest advances in personalized cancer medicine into the standard of care. WIN is built on the recognition that all stakeholders in personalized cancer therapy must collaborate and share information, in order to effectively bring the latest innovations in personalized cancer care to the patient. WIN is a non-profit organization formed by 40 renowned members: Academic cancer centers (25 centers in 16 countries), companies (Blue Cross Blue Shield, Agilent Technologies, GE Healthcare, Oracle Health Services, Foundation Medicine, Millennium Takeda, AstraZeneca and Pfizer), non profit organisation such as EORTC, Fondation ARC and Sage Bionetworks.